logo
logo

Innosign Completes Spin-Out From Philips With An $8M Series A Financing To Revolutionize Precision Medicine Through Its Oncosignal Pathway Activity Profiling Platform

Mar 22, 2022•over 3 years ago

Amount Raised

$8 Million

Round Type

series a

EindhovenFinancial ServicesHealth Care

Description

InnoSIGN, a precision medicine company, today announced that it raised an $8M Series A financing. Proceeds will be used to finance a spin-out from Royal Philips to form a standalone company centered upon the OncoSIGNal pathway activity profiling technology. Investors in the round include Casdin Capital, Life Science Angels, Thuja Capital and Brabant Development Agency. Philips owns a minority stake in the new company.

Company Information

Company

InnoSign

Location

Eindhoven, North Brabant, Netherlands

About

InnoSIGN commercializes its proprietary mRNA based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by obtaining more insight into disease mechanisms to guide patient therapeutic options. OncoSIGNal is available for clinical use in breast cancer as a lab-developed test through InnoSIGN's CLIA laboratory in Mason (OH), for research use through labs in the EU and US as a comprehensive testing service, or as a distributed PCR kit for use in a customer laboratory. The analysis can also be run from RNA-seq data for various cancer and cell types. InnoSIGN utilizes its extensive database with more than 100,000 pathway activity profiles to support drug and diagnostics development.

Related People